Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intralesional triamcinolone for low-grade cutaneous squamous cell carcinoma of the lower leg in older adults
ACTRN12621000851864Phase 2Recruiting
- Sponsor
- Sydney Local Health District
- Start
- Apr 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of triamcinolone acetonide in cutaneous squamous cell carcinoma (cSCC), sponsored by Sydney Local Health District. Started Apr 2024; status: recruiting.
02
Drugs
triamcinolone acetonide
03
Conditions
cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on ACTRN12621000851864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621000851864.